Activation of Akt by SC79 protects myocardiocytes from oxygen and glucose deprivation (OGD)/re-oxygenation
Koulong Zheng, Qing Zhang, Gang Lin, Yefei Li, Zhen-qiang Sheng, Jue Wang, Liang Chen, Hui-He Lu
Abstract
Open-access reader
Koulong Zheng, Qing Zhang, Gang Lin, Yefei Li, Zhen-qiang Sheng, Jue Wang, Liang Chen, Hui-He Lu
Abstract
Open-access reader
// Koulong Zheng 1 , Qing Zhang 1 , Gang Lin 1 , Yefei Li 1 , Zhenqiang Sheng 1 , Jue Wang 1 , Liang Chen 1 , Hui-he Lu 1 1 Department of Cardiology, The Second Affiliated Hospital of Nantong University, Nantong, China Correspondence to: Hui-he Lu, email: nantongluhuihe@163.com Keywords: ischemic heart diseases, oxygen glucose deprivation (OGD), myocardial cells, SC79, Akt Received: December 08, 2016 Accepted: January 11, 2017 Published: January 21, 2017 ABSTRACT SC79 is a novel Akt activator. The current study tested its potential effect against oxygen and glucose deprivation (OGD)/re-oxygenation-induced myocardial cell death. We showed that SC79 activated Akt and protected H9c2 myocardial cells and primary murine myocardiocytes from OGD/re-oxygenation. Reversely, Akt inhibitor MK-2206 or Akt1 shRNA knockdown almost completely abolished SC79-mediated myocardial cytoprotection. SC79 treatment in H9c2 cells inhibited OGD/re-oxygenation-induced programmed necrosis pathway, evidenced by mitochondrial depolarization and cyclophilin D-p53-ANT-1 (adenine nucleotide translocator 1) association. Further, SC79 activated Akt downstream NF-E2-related factor 2 (NRF2) signaling to suppress OGD/re-oxygenation-induced reactive oxygen species (ROS) production. Reversely, NRF2 shRNA knockdown in H9c2 cells largely attenuated SC79-induced ROS scavenging ability and cytoprotection against OGD/re-oxygenation. Together, we conclude that activation of Akt by SC79 protects myocardial cells from OGD/re-oxygenation.
OpenAlex reports 49 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
// Koulong Zheng 1 , Qing Zhang 1 , Gang Lin 1 , Yefei Li 1 , Zhenqiang Sheng 1 , Jue Wang 1 , Liang Chen 1 , Hui-he Lu 1 1 Department of Cardiology, The Second Affiliated Hospital of Nantong University, Nantong, China Correspondence to: Hui-he Lu, email: nantongluhuihe@163.com Keywords: ischemic heart diseases, oxygen glucose deprivation (OGD), myocardial cells, SC79, Akt Received: December 08, 2016 Accepted: January 11, 2017 Published: January 21, 2017 ABSTRACT SC79 is a novel Akt activator. The current study tested its potential effect against oxygen and glucose deprivation (OGD)/re-oxygenation-induced myocardial cell death. We showed that SC79 activated Akt and protected H9c2 myocardial cells and primary murine myocardiocytes from OGD/re-oxygenation. Reversely, Akt inhibitor MK-2206 or Akt1 shRNA knockdown almost completely abolished SC79-mediated myocardial cytoprotection. SC79 treatment in H9c2 cells inhibited OGD/re-oxygenation-induced programmed necrosis pathway, evidenced by mitochondrial depolarization and cyclophilin D-p53-ANT-1 (adenine nucleotide translocator 1) association. Further, SC79 activated Akt downstream NF-E2-related factor 2 (NRF2) signaling to suppress OGD/re-oxygenation-induced reactive oxygen species (ROS) production. Reversely, NRF2 shRNA knockdown in H9c2 cells largely attenuated SC79-induced ROS scavenging ability and cytoprotection against OGD/re-oxygenation. Together, we conclude that activation of Akt by SC79 protects myocardial cells from OGD/re-oxygenation.
Key concepts: Protein kinase B, Medicine, Oxygenation, Cytoprotection, Reactive oxygen species, PI3K/AKT/mTOR pathway, Pharmacology, Apoptosis